Supplementary Information for

Collateral activity of the CRISPR/RfxCas13d system in human cells

Peiguo Shi^{1,*}, Michael R. Murphy¹, Alexis O. Aparicio¹, Jordan S. Kesner¹, Zhou Fang¹, Ziheng Chen^{1,2}, Aditi Trehan¹, Yang Guo¹, Xuebing Wu^{1,*}

¹Department of Medicine and Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032, USA

²Current address: Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA 15213, USA

*Correspondence to: <u>ps3008@cumc.columbia.edu</u> (P.S.), <u>xw2629@cumc.columbia.edu</u> (X.W.)



Supplementary Figure 1. The loss of BFP/GFP depends on the target of the gRNA (i.e., DsRed). (**a-c**), Cells were transfected with RfxCas13d-2A-GFP, DsRed, and either a DsRed targeting gRNA or a non-targeting control gRNA. The fluorescent images (**a**) were quantified in (**b**) and the mRNA changes were quantified in (**c**). (**d-f**), same as (**a-c**) but replacing DsRed with BFP. Note that BFP/GFP are only down-regulated when DsRed is present and targeted by RfxCas13d loaded with a DsRed gRNA. Two-tailed Student's *t*-test was used. **: p<0.01. N=3-4 for all panels. Scale bar, 200 µm. Error bars represent standard deviation.



Supplementary Figure 2. The effect of titrating Cas13d and gRNA expression on collateral activity and on-target knockdown efficiency. (**a**) Fluorescent imaging of cells transfected with Cas13:GFP, DsRed (target), BFP, and either a control gRNA (top row) or a DsRed gRNA (bottom row). (**b**) same as (**a**) (bottom) except Cas13:GFP expression is reduced by transfecting 5, 10, 50, or 100-fold less plasmids. (**c**) Similar to (**b**) but DsRed gRNA expression is reduced. (**d-e**), quantification of (**b-c**), respectively; DsRed and BFP compared with the control group DsRed and BFP, respectively. (**f**) Quantification of BFP signal in **Fig. 1i**., which was then used to generate **Fig. 1j**. Two-way ANOVA was used. **: p<0.01. N=3 for all panels. Scale bar, 200 µm. Error bars represent standard deviation.



Supplementary Figure 3. Targeting DsRed with CRISPR/RfxCas13d led to rRNA degradation (**a**, BioAnalyzer) and a significant reduction of RNA integrity number (RIN) (**b**). The asterisks indicate potential degradation products of the rRNA. Note that the absolute decrease of the RIN number (~10%) is smaller than the decrease in total RNA content (**Fig. 1f**, ~46%), presumably because RIN measures RNA fragmentation and does not capture fragmented RNAs that have been degraded completely by cells prior to RNA extraction. P value was calculated using two-tailed Student's *t*-test. N=3. Error bars represent standard deviation.



Supplementary Figure 4: RfxCas13d-mediated knockdown of endogenous targets. (a) qPCR quantification of knockdown efficiency for each target. (b) Targeting four abundant endogenous transcripts resulted in rRNA degradation (BioAnalyzer assay similar to **Supplementary Fig. 3**). Three to six biological replicates were shown for each target. (c) Similar to (b) but comparing high, medium, and low abundance targets. (d), RNA integrity number (RIN) quantified from (c). (e-m) Cells transfected with RfxCas13d:GFP, and a control gRNA (e), ACTG1 gRNAs (f), or HNRNPA2B1 gRNAs (g). The fluorescent images (e-g) were quantified in (h-i) and the mRNA changes were quantified in (j-k), respectively. The correlation between target mRNA knockdown and collateral activity (GFP) for *ACTG1* and *HNRNPA2B1* targeting were shown in (I-m), respectively. r: Pearson's correlation coefficient. Two-tailed Student's *t*-test for (a). Two-way ANOVA test for (d, h-k). **: p<0.01. N=3 or 4 for all panels. Error bars represent standard deviation.



Supplementary Figure 5. siRNA-mediated knockdown of *HNRNPA2B1* or *HNRNPL* did not result in down-regulation of the transcriptome (relative to mitochondrial RNA). P value was calculated using Wilcoxon Rank Sum Test.



Supplementary Figure 6. Change in cell proliferation (WST-1 assay) in cells transfected with varying amount of DsRed plasmids, together with a fixed amount of RfxCas13d and gRNA plasmids. Two-way ANOVA was performed to obtain the P value. *: p<0.05; **: p<0.01. N=3. Error bars represent standard deviation.



LC3

(s.e)

β-ΑCTIN

-15

—40 (kDa) DsRed gRNA

Supplementary Figure 7. DsRed-induced RfxCas13d collateral activity does not cause cell death. HEK293T cells were transfected with DsRed, RfxCas13d-2A-GFP, and either a DsRed-targeting gRNA or a non-targeting control gRNA. No difference was detected with trypan blue-based cell death assay (**a**), Annexin V - APC / DAPI cell apoptosis assay (**b**), LC3 cleavage (autophagy) (**c**), or Caspase3 cleavage (apoptosis) (**d**). Two-tailed Student's *t*-test was used to calculate P values. N=3 for all panels. Scale bar, 50 μm. Error bars represent standard deviation.



Supplementary Figure 8. siRNA-mediated knockdown of abundant endogenous mRNAs did not affect cell proliferation. (**a-d**), knockdown efficiency for *FTH1*, *HNRNPA2B1*, *ACTG1*, and *MIF*, respectively. (**e**), Relative cell proliferation (WST-1) comparing knockdown and controls. For (**a-d**), two-tailed Student's *t*-test was performed to calculate P values. For (**e**), two-way ANOVA was performed to calculate the P value. **: p<0.01. N=3-4 for all panels. Error bars represent standard deviation.



Supplementary Figure 9. (a) Raw gel image for (Fig. 1d). (b) Raw gel image for (Supplementary Figure 7c).

а

gRNA	Sequence
DsRed	GGAGGTCAAAACAGCGTGGATG
DsRed gRNA 2	TGGCGTCTCCAGGCGATCTGAC
DsRed gRNA 3	ACAGCGTGGATGGCGTCTCCAG
DsRed gRNA 4	TGTCTTCTATGGAGGTCAAAAC
DsRed gRNA 5	AGGCCGCCGGTGTCTTCTATGG
DsRed gRNA 6	CGGTAGCGCTAGGCCGCCGGTG
DsRed gRNA 7	GATCTGAGTCCGGTAGCGCTAG
DsRed gRNA 8	GCGACCGGTGGATCTGAGTCCG
DsRed gRNA 9	GGCCATGGTGGCGACCGGTGGA
DsRed gRNA 10	CCTCGGAGGAGGCCATGGTGGC
Control (for DsRed)	GTTTTGACCTCCATAGAAGACA
MIF	GTTTACGATGAACATCGGCATGA
ACTG1	AGAATGAATACATTTACAGGCGT
ACTG1 gRNA 2	CTCAAAGCAAGTAACAGCCCACG
ACTG1 gRNA 3	AGCCATTGTCAATGACCAGCGCG
HNRNPA2B1	GTTTCAAAGCTTAAGCCACCAAT
HNRNPA2B1 gRNA 2	TCCTATTTATACAGTGAAGCCCA
HNRNPA2B1 gRNA 3	CCATAGTTGTCATAACCACCTCC
FTH1	TGTCAAAGAGATATTCCGCCAAG
CLIC1	ATTTGGCAAATATGTCCAGCCCA
VDAC2	GACGTTGAAAATTCCACGCCACT
CD99	GTTAGTAAACATCATCCGCCCAG
CLTA	CAGAATAATGCACAGAAGCACAG
ANXA4	CTTTACTATAGCCAGCAGAGCAT
B4GALNT1	ATGACAAGAAGAAGCCAGTCTGC
HECTD3	TCCCAGAAATACTGCACCCGCGA
Control (for endogenous genes)	TCACCAGAAGCGTACCATACTCA

Supplementary Table 1: Guide RNA (gRNA) spacer sequences.

Supplementary Table 2: RT-qPCR primers sequences.

Primer	Sequence
<i>mGapdh</i> -qPCR-F	TGAAGCAGGCATCTGAGGG
<i>mGapdh</i> -qPCR-R	CGAAGGTGGAAGAGTGGGAG
<i>MT-CO2</i> -qPCR-F	CCGTCTGAACTATCCTGCCC
MT-CO2-qPCR-R	GAGGGATCGTTGACCTCGTC
Cas13d-qPCR-F	GGTCTACACCATGATGGACTTT
Cas13d-qPCR-R	CGCTCAGGGACTTCTCATTATC
<i>BFP</i> -qPCR-F	GAGAGTCACCACATACGAAGAC
<i>BFP</i> -qPCR-R	CCCTCTGATCTTGACGTTGTAG
<i>GFP</i> -qPCR-F	GAACCGCATCGAGCTGAA
<i>GFP</i> -qPCR-R	TGCTTGTCGGCCATGATATAG
<i>DsRed</i> -qPCR-F	CCCCGTAATGCAGAAGAAGA
<i>DsRed</i> -qPCR-R	GGTGATGTCCAGCTTGGAGT
<i>FTH1</i> -qPCR-F	CCCCCATTTGTGTGACTTCAT
<i>FTH1</i> -qPCR-R	GCCCGAGGCTTAGCTTTCATT
<i>HNRNPA2B1</i> -qPCR-F	TTTGGGGATGGCTATAATGG
<i>HNRNPA2B1</i> -qPCR-R	CTGGTTGCCATATCCAGGTC
ACTG1-qPCR-F	CCATCATGAAGTGTGACGTG
ACTG1-qPCR-R	ACACCGAGTACTTGCGCTCT
<i>MIF</i> -qPCR-F	TCATCGTAAACACCAACGTG
<i>MIF</i> -qPCR-R	GAAGGCCATGAGCTGGTC
VDAC2-qPCR-F	TTGATACTACCTTCTCACCAAACAC
VDAC2-qPCR-R	TCAAAGTCAACATCACAACCAA
CD99-qPCR-F	AACCCACCCAAACCGATGC
CD99-qPCR-R	TGAAAAGCTACCGGAGGAACTA
<i>CLTA</i> -qPCR-F	CTTCGCTGACGTGATTGGTTA
<i>CLTA</i> -qPCR-R	GCCTGTTCTAGGCTGTAGCAA
CLIC1-qPCR-F	ACCGCAGGTCGAATTGTTC
CLIC1-qPCR-R	ACGGTGGTAACATTGAAGGTG
HECTD3-qPCR-F	CATCGCCTGGGATCGAGAC
HECTD3-qPCR-R	CGCACTCGTAGGTCCATGTC
ANXA4-qPCR-F	GGAGGTACTGTCAAAGCTGCT
ANXA4-qPCR-R	GGCAAGGACGCTAATAATGGC
<i>B4GALNT1-</i> qPCR-F	CAGAAACAAGTCCGAGCTATTGA
<i>B4GALNT1-</i> qPCR-R	GAGGGGCTGAACTTCCACAC